APLT News and Press, Applied Therapeutics Inc. From 04/07/21

NEW YORK, April 07, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced a poster presentat...

Applied Therapeutics (APLT): FY GAAP EPS of -$4.28 beats by $0.26.Cash and cash equivalents and short-term investments of $96.8MPress Release For further details see: Applied Therapeutics EPS beats by $0.26

AT-007 ACTION-Galactosemia Kids pediatric clinical study recently resumed following discussions with FDA On track to submit NDA for AT-007 in Galactosemia no later than Q3 2021; Commercial preparations underway ARISE-HF Phase 3 global registrational study of AT-001 in Di...

NEW YORK, March 16, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced it will host a Vir...

NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will p...

NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today...

Applied Therapeutics (APLT) has priced its 3M common shares at $23.00/share, for expected gross proceeds of $69M.Underwriters over-allotment is an additional 450K shares.Net proceeds will be used for the development of clinical and preclinical product candidates, for commercialization and oth...

NEW YORK, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today...

Applied Therapeutics (APLT) is planning an underwritten public offering of 3M shares.Applied also expects to grant the underwriters a 30-day option to purchase up to an additional 450K shares.Goldman Sachs, Cowen and UBS are joint book-runners.Applied shares closed down 2.9% to...

NEW YORK, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today...